Drug Type Small molecule drug |
Synonyms Lomibuvir (USAN/INN) |
Target |
Action inhibitors |
Mechanism NS5B polymerase inhibitors(Hepatitis C virus NS5B RNA-dependent RNA polymerase inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC25H35NO4S |
InChIKeyWPMJNLCLKAKMLA-VVPTUSLJSA-N |
CAS Registry1026785-55-6 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Fibrosis | Phase 2 | United Kingdom | 01 Feb 2012 | |
Fibrosis | Phase 2 | United States | 01 Feb 2012 | |
Fibrosis | Phase 2 | Germany | 01 Feb 2012 | |
Fibrosis | Phase 2 | Canada | 01 Feb 2012 | |
Fibrosis | Phase 2 | Poland | 01 Feb 2012 | |
Chronic hepatitis C genotype 1 | Phase 2 | New Zealand | 01 Aug 2010 | |
Chronic hepatitis C genotype 1 | Phase 2 | United States | 01 Aug 2010 | |
Chronic hepatitis C genotype 1 | Phase 2 | New Zealand | 01 Aug 2010 | |
Chronic hepatitis C genotype 1 | Phase 2 | United States | 01 Aug 2010 |
Phase 2 | 152 | (lomskvjael) = jrwexzyzhy hkfrglvrar (pavrgzoufa ) | - | 01 Jul 2014 | |||
(lomskvjael) = caxroqizay hkfrglvrar (pavrgzoufa ) |